Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02281084
Title Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene Corporation
Indications

myelodysplastic syndrome

Therapies

Azacitidine

Azacitidine + Durvalumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.